+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

This trial investigates the use of IgPro20 in adults with secondary immune deficiency caused by blood cancers who have been treated with B-cell targeting CAR T-cell therapy or T-cell engager bispecific antibody therapy. The study aims to evaluate the safety, effectiveness, and how the body processes IgPro20, focusing on reducing serious bacterial infections. Participants include adults diagnosed with specific blood cancers like multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin lymphoma, or B-cell acute lymphoblastic leukemia who have responded to their prior therapies. Participants are divided into two groups based on their immunoglobulin G IgG levels. Those with low IgG receive a loading dose of IgPro20 under the skin daily for five days, followed by weekly doses for a year. Those with higher IgG levels and ongoing immunoglobulin therapy receive weekly IgPro20 injections for 52 weeks. The IgPro20 is given as subcutaneous infusions, and the study is open-label and conducted at multiple centers. During the study, participants will have regular visits for up to 12 months to monitor infections, hospitalizations, use of anti-infective medications, and side effects. Blood samples will be collected to measure IgG levels and pharmacokinetics. Researchers will observe the rate of serious bacterial infections as the primary outcome, along with other infection-related and safety measures. The total participation duration is approximately one year.

Age: 18Years +All GendersPhase 3
60 locations